MedTrace Logo

Endometrial Rejuvenation Study

NCT04045821 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-05-19

No results posted yet for this study

Summary

To evaluate the response of the endometrial lining after subcutaneous administration of the medication AMD3100. This medication mobilizes stem cells and will be used in a population of infertile women with a thin endometrium who are undergoing frozen-thawed embryo transfer. The investigators will assess associations between response to stem cell mobilization and pregnancy outcomes.

Conditions

  • Infertility of Uterine Origin

Interventions

DRUG

AMD3100

Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose

DRUG

Normal saline

Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose

PROCEDURE

dilation and curettage

all participants will undergo routine D\&C procedure

Sponsors & Collaborators

  • Reproductive Medicine Associates of New Jersey

    lead OTHER

Principal Investigators

  • Brent Hanson, MD · Reproductive Medicine Associates of New Jersey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-17
Primary Completion
2021-01-27
Completion
2021-05-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045821 on ClinicalTrials.gov